The Clinical Efficacy of Type 2 Inflammation-Specific Agents Targeting Interleukins in Reducing Exacerbations in Severe Asthma: A Meta-Analysis.

Published in: Yonsei medical journal (2022)

Our findings suggest that T2-specific agents are significantly associated with a reduced rate of AE, compared with placebo. Their efficacy appears to be enhanced in patients with eosinophil counts of ≥300 cells/µL.

Keyphrases

induced apoptosis
chronic obstructive pulmonary disease
oxidative stress
cell cycle arrest
cancer therapy
randomized controlled trial
clinical trial
peripheral blood
endoplasmic reticulum stress
cell death
phase iii
cell proliferation